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Pellissier JM2, Peloso P5, Sen S2, Mohamed A4, Gonzalez JM4
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USA; 3University of Southampton, Southampton, UK, UK; 4RTI Health Solutions, Research 
Triangle Park, NC, USA; 5MRL, Whitehouse Station, NJ, USA
BACKGROUND: Treatments for symptom control in osteoarthritis (OA) confer 
varying degrees of beneﬁ ts alongside medication-related risks. Physicians’ preferences 
over beneﬁ ts and risks of NSAIDS are an important aspect of understanding clinical 
practice. OBJECTIVES: To estimate physicians’ preferences over beneﬁ ts and risks 
associated with NSAID use in the management of OA and examine differences in 
preferences between general practitioners (GPs) and specialists. METHODS: Partici-
pating physicians treated at least 10 OA patients per-month. Each physician was 
randomized to receive one of four blocks of discrete-choice questions; each block 
consisting of 12 paired choice tasks comparing treatment proﬁ les. Treatment proﬁ les 
were deﬁ ned by four beneﬁ ts (ambulatory pain, resting pain, stiffness, difﬁ culty doing 
daily activities) and four medication-related risks (bleeding ulcer, stroke, heart attack, 
hypertension), each varying across four clinically meaningful levels. Elicitation of 
preferences was facilitated using standardized patient proﬁ les systematically varying 
by age, co-morbid conditions and clinically relevant risks of NSAIDs. Preference 
weights were estimated using mixed-effects logistic regression and were standardized 
on a 0–10 (low-high) importance scale. RESULTS: 477 physicians participated (61% 
GPs, 39% specialists). Reductions in ambulatory pain and difﬁ culty doing daily activi-
ties were the most important efﬁ cacy variables (6.45; 95%CI:4.8–8.2) followed by 
eliminating resting pain (3.18; 95%CI:1.9–4.5) and stiffness (2.79; 95%CI:1.5–4.1). 
Ambulatory pain was twice as important as resting pain or stiffness (P < 0.05). Risk 
of heart attack was the most important medication-related risk outcome (10.00; 
95%CI:7.6–12.4) followed by stroke (9.42; 95%CI:7.2–11.6), ulcer risk (4.62; 
95%CI:3.5–5.7) and hypertension (3.25; 95%CI:3.2–3.4). There were no statistically 
signiﬁ cant differences in preferences between GPs and specialists. CONCLUSIONS: 
Ambulatory pain and the incremental risk of heart attack were the most important 
NSAID-related attributes that inﬂ uence physicians’ treatment choices. Preferences did 
not vary between GPs and specialists. The ﬁ ndings conﬁ rm that beneﬁ t-risk tradeoffs 
are important aspects in treament selection for OA management.
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ECONOMY OF NSAIDS IN THE MANAGEMENT OF OSTEOARTHRITIS: 
SODIUM CHONDROITIN SULFATE VS. CONTROL GROUP
Taieb C, Pibourdin JM
Pierre Fabre, Boulogne, France
OBJECTIVES: Describe the potential economy of NSAIDs in a population of patients 
with osteoarthritis newly-treated with a sodium chondroitin sulphate (SCS) versus a 
control group. METHODS: The Disease Analyzer database (IMS), which collects 
medical data from 1240 representative French GPs was used. The control group 
consists of patient diagnosed with knee or hip osteoarthritis during the observation 
period but not treated with symptomatic slow acting drugs for osteoarthritis through-
out the study period, no during the year before the study or the following year. 
RESULTS: In total, 944 patients were included, 472 per group. The characteristics of 
both groups in terms of age, sex, time since diagnosis and type of osteoarthritis are 
strictly the same. 80% of patients included suffer from osteoarthritis of the knee. a 
total of 53.4% of patients included in study received one or more prescriptions for 
NSAIDs during the year prior to their inclusion. Half of the patients in the SCS group 
received at least one NSAID prescription during initiation or during the 1 year follow-
up period. This % is signiﬁ cantly higher in the control group (64%; P < 0.01). 18% 
of patients in the SCS group stopped their treatment with NSAIDs at the initiation of 
SCS and did not resume it during the follow-up year, versus 11% in the control group. 
This difference is signiﬁ cant (p = 0.01). Patients in the SCS group require signiﬁ cantly 
fewer days of treatment with NSAIDs expressed in DDD than patients in the control 
group: on average 49 days of treatment versus 64 (p = 0.01). CONCLUSIONS: One 
of the public health goals set by health authorities—to reduce the incidence of iatro-
genic complications (serious bleeding or gastroduodenal events) by 20% in osteoar-
thritic patients could be attained by a prescription of SCS. Indeed, this study highlights 
the fact that, in actual use, patients in the SCS group are signiﬁ cantly less likely to use 
NSAIDs (−22%).
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THE MANAGEMENT OF OSTEOARTHRITIS: ECONOMY OF NSAIDS
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OBJECTIVES: To describe the use NSAIDs in a population of patients with osteoar-
thritis newly-treated (2009) by a symptomatic slow acting drugs for Osteoarthritis 
(SYSADOA) METHODS: The Disease Analyzer database (IMS), which collects 
medical data from 1240 representative French GPs was used. Patients over 50 y of 
age were included over a period of one year where a diagnosis of osteoarthritis associ-
ated with the initiation of an SYSADOA prescription was identiﬁ ed in the DA database 
(patient had been monitored for at least 6 months). RESULTS: In total, 3141 patients 
were included in the study. The patient proﬁ le is similar regardless of the treatment 
group considered (68% female, average age of 66, 50% patients the diagnosis dates 
from less than 1 year). The use of NSAIDs at the outset does not signiﬁ cantly differ 
among the groups of patients (25%). About 30% of patients discontinue their NSAID 
therapy upon initiation of treatment with SYSADOA. This proportion did not vary 
signiﬁ cantly with the SYSADOA considered. More than 40% of patients discontinued 
treatment with NSAIDs during the 6-month follow-up period. 20% of patients who 
continued treatment with NSAIDs increased the dosage or duration of the NSAID 
therapy. About 45% of patients beneﬁ ted from a co-prescription of analgesics during 
the initiation of treatment with SYSADOA. This rate did not signiﬁ cantly vary among 
groups of patients. 21% of patients discontinued their treatment with analgesics after 
initiation of treatment with SSAAO. This proportion did not vary signiﬁ cantly with 
the SYSADOA considered. CONCLUSIONS: It is generally accepted that an economy 
of 20% of NSAIDs has a major impact on public health. Regardless of the prescribed 
SYSADOA, NSAID interruptions at initiation are approximately 30%, and nearly two 
thirds of patients with co-prescriptions of NSAIDs at the start of treatment stop or 
reduce this treatment within 6 months. The cost of complications related to anti-
inﬂ ammatory drugs would be around 150 million Euros. 
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AGENTS WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID 
ARTHRITIS AND ACTIVE DISEASE DESPITE METHOTREXATE THERAPY
Lebmeier M1, Pericleous L1, Guyot P2, Baig H1, Christensen R3, Bergman G2, Taylor PC4, 
Drost P5
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OBJECTIVES: To compare the efﬁ cacy in terms of HAQ score between abatacept and 
other biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in patients with 
rheumatoid arthritis taking concomitant methotrexate (MTX) who have inadequate 
response to MTX (MTX-IR). METHODS: A systematic literature review identiﬁ ed 
controlled trials investigating the efﬁ cacy of abatacept (3 studies), etanercept (2), 
inﬂ iximab (3), adalimumab (2), certolizumab pegol (2) ritixumab (2), and tocilizumab 
(1) in MTX-IR patients. The identiﬁ ed trials were comparable in design, included 
patients, and concomitant treatment (MTX). Mixed treatment comparison analyses 
were performed on HAQ change from baseline (CFB) at 24 and 52 weeks. Results 
were expressed as difference in HAQ CFB score between treatments and expected 
HAQ CFB and the 95% Credible Interval (CrI) per treatment at 24 and 52 weeks. 
RESULTS: The analysis of HAQ CFB at 24 weeks showed that abatacept/MTX is 
more efﬁ cacious than MTX monotherapy (−0.30, 95%CrI: −0.40; −0.19) and shows 
small numeric differences versus other biologics/MTX (range: −0.11:0.08). The 
expected mean HAQ CFB at 24 weeks for abatacept (−0.58) was superior to placebo 
(−0.28) and comparable to all the alternative treatments (adjusted mean between −0.47 
and −0.66). The ﬁ ndings at 52 weeks are in line with those at 24-weeks, although no 
data was available for tocilizumab and golimumab. Scenario analyses conﬁ rmed the 
robustness of the ﬁ ndings. CONCLUSIONS: All biologic DMARDs in combination 
with MTX in the treatment of MTX-IR patients resulted in improvements from 
baseline in HAQ score compared to MTX monotherapy at 24 and 52 weeks. All 
biologic DMARDs in combination with MTX are expected to result in a comparable 
improvement in HAQ score.
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RESULTS TO DECISION-MAKERS EVERYDAY PRACTICE
Marinho M1, Schiola A2, Pimentel A2, Santoni N2, Teich V1, Clark LGO3
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OBJECTIVES: Interfaces are interactive dashboards built with programs like Visual 
Basic for Applications, Crystal Xcelsius or Java. We aimed to demonstrate how IEI 
allow the translation of pharmacoeconomic studies’ results into understandable pro-
jections to decision makers. We present the economic evaluation of rivaroxaban in 
the prevention of thromboembolic events as a case study. METHODS: A model evalu-
ating rivaroxaban in patients undergoing total knee and hip replacement was used. 
The model was adapted to different decision makers needs, namely Health Mainte-
nance Organizations (HMO), hospitals, and physicians focused only on clinical out-
comes. For each perspective, the following parameters could be customized: state 
taxes, time horizon of the analysis, choice of comparator (enoxaparin, dabigatran or 
both), duration of hospitalization, unit costs (drugs, treatment and diagnosis 
resources), eligible population and market share of comparators over the following 
ﬁ ve years. RESULTS: The IEI design for this case demonstrated that, under the per-
spective of an HMO with 200.000 lives, considering a base case where 80% of patients 
are treated with enoxaparin and 20% with dabigatran, and replacing every year 10% 
of enoxaparin cases with rivaroxaban would result in a budget impact of (-R$46,155) 
in 4 years for knee and hip replacement cases. The potential impact for cost offsets 
for the whole private system would be of (-R$8.3 million). Under the perspective of 
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a hospital performing 50 knee and 50 hip surgeries every year, this potential for cost-
offsets would be of (-R$108,850). This would vary a lot for the perspective of HMOs 
and hospitals of different sizes, as well as depending on the costs of each decision 
maker, demanding constant customization of parameters. CONCLUSIONS: The use 
of IEI makes the pharmacoeconomic studies results more intelligible to decision 
makers, permitting them to foresee their actual application on a real practice, in dif-
ferent scenarios.
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LINKAGE OF ADMINISTRATIVE AND MEDICAL RECORDS DATABASES 
FOR INVESTIGATING PHARMACEUTICAL USE AND OUTCOMES
Huse DM1, Bizier R1, Tomic K2
1Thomson Reuters, Cambridge, MA, USA; 2Thomson Reuters, Washington, DC, USA
BACKGROUND: Use of electronic health care databases to examine pharmaceutical 
use and effects faces limitations inherent in the source of data. Medical records docu-
ment prescribing but not consumption of medication; administrative databases docu-
ment dispensing but not the original intent of the prescriber. OBJECTIVES: To 
evaluate a patient-level linked database of electronic medical records (EMR) and 
administrative claim for use in measuring both prescribing and dispensing of pharma-
ceuticals. METHODS: Claims data from Thomson Reuters MarketScan database were 
linked to the GE Centricity EMR database using probabilistic methods to overcome 
the de-identiﬁ cation required of both databases under US privacy laws. Patient-level 
records were matched based on demographic characteristics and calendar dates of 
physician visits. Multiple visits were required to reduce the likelihood of mismatches. 
The agreement between prescribing records in the EMR and claims for dispensing of 
medication was explored in the context of self-administered medication for osteopo-
rosis, including bisphosphonates and raloxifene. RESULTS: Using data from 2004–
2009, 219,529 patients were matched between the two data sources. Mean age was 
43 years and 57% were female. We identiﬁ ed 2,331 patients whose medical record 
showed new prescriptions for bisphosphonates or raloxifene (no evidence of use in 
the prior 180 days). Pharmacy claims indicated these prescriptions were ﬁ lled by 56% 
of patients within 7 days, 75% within 30 days, and 86% within 90 days. CONCLU-
SIONS: It is to be expected that there will be some degree of noncompliance, hence 
incomplete ﬁ lling of prescriptions, as observed. The lag from dispensing to prescribing 
among many patients is also consistent with use of samples for initial prescriptions. 
Overall, the example of osteoporosis therapy shows consistency between prescribing 
in EMR data and dispensing in claims data among a sample of probabilistically linked 
patient records.
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CLAIMS-BASED SEVERITY INDEX FOR RHEUMATOID ARTHRITIS FROM 
HEALTH CARE CLAIMS DATA
Baser O1, Gust C2, Akin C3
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OBJECTIVES: Controlling for disease severity in observational studies is crucial to 
get an estimate with no selection bias. However, outcomes research studies using 
claims data, contain no information about disease severity. Therefore, comorbid scores 
are used for a proxy for the disease severity. There exists no severity score speciﬁ c for 
rheumatoid arthritis (RA). The goal of this study was to develop a severity index for 
rheumatoid arthritis (SIFRA) for private health care claims data. METHODS: We 
extracted the following variables related to rheumatoid arthritis from the claims data: 
total number of synthetic disease-modifying anti-rheumatic drugs (DMARDs), total 
number of biological DMARDs, tests for C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) ordered, rehabilitation visits, rheumatology visits, Felty’s 
syndrome and Sjogren’s syndrome, pulmonary, soft tissue nodules, joint surgery, 
number of platelet counts and chemical panels ordered, and rheumatoid factors 
testing. a linear regression model was used to create the severity score. The severity 
score was compared with the rheumatoid arthritis medical records-based index of 
severity (RARBIS) and currently-used comorbidity scores to proxy severity in out-
comes research studies related with rheumatoid arthritis. RESULTS: According to the 
Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), log likeli-
hood function, R-squared values and average squared prediction error, SIFRA per-
formed better than RARBIS, Charlson Comorbidity Score (CCI), Elixhauser 
comorbidity score and Chronic disease score. Spearman correlation with RARBIS was 
0.65 and signiﬁ cant. However, the correlation with the Charlson Comorbidity Index 
(0.1, p = 0.6521), Elixhauser Index (0.15, p = 0.5312) and Chronic disease score (0.13, 
p = 0.6011) were low and insigniﬁ cant. CONCLUSIONS: Comorbidity scores (Charl-
son, Elixhauser or Chronic Disease Scores) commonly used in outcomes research are 
inadequate to be proxy variable for RA patients. SIFRA, at least for rheumatoid 
arthritis, controls for disease severity better than any other commonly used measure.
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MODELING OF RHEUMATOID ARTHRITIS: A METHODOLOGICAL 
APPROACH
Taylor MJ1, Righetti C1, Conway P2, Lebmeier M3
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OBJECTIVES: Reimbursement agencies like the United Kingdom (UK) National Insti-
tute for health and Clinical Excellence (NICE) use mathematical modelling to analyze 
the costs and beneﬁ ts of health care technologies. The structure of these models is not 
pre-speciﬁ ed, but dependent on the requirements of the decision problem on hand. 
Various decision-analytic models have been developed to assess the potential clinical 
and economic beneﬁ ts of several RA treatment regimes, including anti-TNF agents 
and early use of disease-modifying anti-rheumatic drugs (DMARDs). The main objec-
tive is to provide a guide on how to model treatment options for early rheumatoid 
arthritis, in particular etanercept. Thus, it sought to address the methodological issues 
relating to the choice of modeling technique. RESULTS: Previous analyses have used 
a variety of modelling approaches to model treatment options for RA. The rationale 
for the choice of model structure is rarely discussed in published studies and can affect 
the results produced. Advances in the treatment of RA make it necessary to develop 
a model which is ﬂ exible enough to account for different attributes (e.g. clinical remis-
sion, radiographic non-progression, and functional status), but does not increase the 
complexity of the model to an amount where it becomes too difﬁ cult to populate it 
with relevant data. Individual level models offer a solution to this problem by simulat-
ing the progression of each individual with different characteristics, where non-
Markovian distributions allow greater ﬂ exibility in modelling the timing of events. 
Further, based on the characteristics of the disease, the model should assume indepen-
dence between individuals, whilst, based on its treatment options, as assessment of 
adequate treatment response is important, time should be modeled. CONCLUSIONS: 
This work suggests that future analyses should use individual sampling models (e.g. 
simulated patient-level Markov models) for modelling the costs and beneﬁ ts of treat-
ments for RA.
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A LONGITUDINAL COMPARISON OF MAPPING EQUATIONS DERIVED 
FROM BASELINE AND POST-INTERVENTION DATA
Kontodimopoulos N1, Bozios P2, Elmatzoglou I2, Raftakis I2, Yfantopoulos J3, Niakas D1
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OBJECTIVES: Mapping from disease-speciﬁ c to utility measures is a research area 
gaining increasing attention. However, few studies have assessed the longitudinal 
validity of mapping models and none, to our knowledge, have compared models 
derived from baseline and post-intervention patient data. This study examined models 
derived from time-differing patient data, for mapping the Modiﬁ ed Health Assessment 
Questionnaire (MHAQ) on to the EQ-5D. METHODS: A total of 120 rheumatoid 
arthritis patients (60.0% female, mean age 59.0) completed the MHAQ and EQ-5D 
at baseline, and 3, 6 and 12 months after administration of an anti-TNFa or another 
biological agent. OLS regression produced mapping equations from baseline and post-
intervention data. Model predictive ability and explanatory power were assessed by 
root mean square error (RMSE) and adjusted R2 respectively. Pearson’s r and intra-
class correlation coefﬁ cient (ICC) assessed association and level of agreement between 
predicted and reported utilities. RESULTS: R2 (baseline, 3, 6 and to 12 months) was 
0.452, 0.418, 0.541 and 0.413 respectively, whereas prediction errors were 13.0%, 
11.1%, 8.1% and 7.2%. All equations produced a range of scores comparable to 
those achieved by the standard EQ-5D scoring algorithm, as well as strong correlations 
and agreement between reported and predicted utilities. The baseline and 12-month 
models appeared to under- and overestimate EQ-5D scores respectively, whereas the 
6-month model generated the smallest differences, typically less than the minimally 
important difference for the EQ-5D (0.03). CONCLUSIONS: Baseline data, which 
typically corresponds to lower patient HRQOL, may give mapping equations with 
compromised predictive ability, compared to models generated from post-intervention 
data, and this study showed that this factor is worth examining when longitudinal 
data are available. The next step in this line of research is to test QALY estimates and 
cost-utility increments derived from baseline and post-intervention mapping 
algorithms.
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THE DETERMINANTS OF SOCIAL ROLES AMONG RHEUMATOID 
ARTHRITIS PATIENTS—DATA FROM THE NDB PORTUGAL COHORT
Chaves I1, Marques R1, Vasconcelos J1, Pedro S1, Rodrigues A1, Michaud K2, Wolfe F3, 
Garcia E1
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BACKGROUND: An important consequence of rheumatoid arthritis (RA) is disabil-
ity, traditionally assessed by the Health Assessment Questionnaire (HAQ), which 
captures the physical component. Disability can also be evaluated by restricted per-
formance of social roles and those predictors haven’t been extensively studied. OBJEC-
TIVES: Determinants of social roles, among RA patients, as evaluated by paid work 
and social functioning were studied. METHODS: A total of 1,140 RA patients from 
the NDB-Portugal longitudinal cohort were analyzed. Univariate (UV) and Multivari-
ate (MV) generalized estimating equations were used to assess whether the following 
factors were determinants of paid work (1 = yes 0 = no, OR; 95%CI) and of SF-36 
social functioning (0–100, 100 is best, β; 95%CI): age, sex, marital status, educational 
level, number of people living in patient’s household, dependence on others, RA dura-
tion, number of major comorbidities, TNF, anxiolytic and/or antidepressant use, 
HAQ, disease activity (RADAI), quality of life (VASQOL), pain, fatigue and sleep 
disturbances (VAS scales, 0–10, 10 is worst). RESULTS: In MV analysis the odds of 
having a form of paid work increased with higher education (1.17; 1.12, 1.22) and 
better VASQOL (1.92; 1.15, 3.20) and decreased with higher age (0.91; 0.90, 0.93), 
